These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23934237)

  • 1. Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage.
    Offord S; Lin J; Wong B; Mirski D; Baker RA
    Community Ment Health J; 2013 Dec; 49(6):625-9. PubMed ID: 23934237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population.
    Joshi K; Muser E; Xu Y; Schwab P; Datar M; Suehs B
    J Comp Eff Res; 2018 Aug; 7(8):723-735. PubMed ID: 29722547
    [No Abstract]   [Full Text] [Related]  

  • 4. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
    Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Medication Nonadherence and Comorbidity on Health Resource Utilization in Schizophrenia.
    Desai R; Nayak R
    J Manag Care Spec Pharm; 2019 Jan; 25(1):37-46. PubMed ID: 30589635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodological considerations in estimating adherence and persistence for a long-acting injectable medication.
    Campagna EJ; Muser E; Parks J; Morrato EH
    J Manag Care Spec Pharm; 2014 Jul; 20(7):756-66. PubMed ID: 24967528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.
    Lin J; Wong B; Offord S; Mirski D
    J Behav Health Serv Res; 2013 Jul; 40(3):355-66. PubMed ID: 23579871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment adherence in newly diagnosed type 2 diabetes: patient characteristics and long-term impact of adherence on inpatient care utilization.
    Sun P; Lian J
    Postgrad Med; 2016 May; 128(4):338-45. PubMed ID: 26849064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
    Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
    Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication.
    Richards K; Johnsrud M; Zacker C; Sasané R
    Adm Policy Ment Health; 2024 Mar; 51(2):207-216. PubMed ID: 38071724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
    Lang K; Federico V; Muser E; Menzin J; Menzin J
    J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
    Joshi K; Pan X; Wang R; Yang E; Benson C
    Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.
    Markowitz M; Karve S; Panish J; Candrilli SD; Alphs L
    BMC Psychiatry; 2013 Oct; 13():246. PubMed ID: 24094241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Descriptive analysis of mail interventions with physicians and patients to improve adherence with antihypertensive and antidiabetic medications in a mixed-model managed care organization of commercial and Medicare members.
    Jing S; Naliboff A; Kaufman MB; Choy M
    J Manag Care Pharm; 2011 Jun; 17(5):355-66. PubMed ID: 21657805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to oral diabetes medications among users and nonusers of antipsychotic medication.
    Desai PR; Adeyemi AO; Richards KM; Lawson KA
    Psychiatr Serv; 2014 Feb; 65(2):215-20. PubMed ID: 24233254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.